Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus

Watanabe, Ichiro, Tomita, Aiko, Shimizu, Miho, Sugawara, Mie, Yasumo, Hiroaki, Koishi, Ryuta, Takahashi, Tohru, Miyoshi, Kaoru, Nakamura, Kouichi, Izumi, Takashi, Matsushita, Yasuyuki, Furukawa, Hidehiko, Haruyama, Hideyuki, Koga, Teiichiro·2003·Clinical Pharmacology & Therapeutics

Abstract

Background and objective: Troglitazone is a 2,4‐thiazolidinedione antidiabetic agent with insulin‐sensitizing activities. This agent had been used efficiently in a large number of patients but was withdrawn from the market in March 2000 because of its association with idiosyncratic hepatotoxicity. To address the susceptible genetic factors responsible for the hepatotoxicity associated with this agent, we performed a genetic polymorphic analysis by a target gene approach in troglitazone‐treated Japanese patients with type 2 diabetes mellitus. Methods: One hundred ten patients treated with troglitazone were recruited into this study. The case patients (n = 25) were recruited through medical professionals who had previously reported abnormal increases in the levels of ALT or AST among their patients. The control patients (n = 85) were recruited through physicians prescribing troglitazone. For statistical accuracy, efforts were made to maximize the size of the case group. Genotype analysis was performed in 68 polymorphic sites of 51 candidate genes related to drug metabolism, apoptosis, roduction and elimination of reactive oxygen species, and signal transduction pathways of peroxisome proliferator–activated receptor gamma 2 and insulin. Results: The strong correlation with transaminase elevations was observed in the combined glutathione‐S‐transferase GSTT1‐GSTM1 null genotype (odds ratio, 3.692; 95% confidence interval, 1.354‐10.066; P = .008). Conclusions: The double null mutation of GSTT1 and GSTM1 might influence troglitazone‐associated abnormal increases of liver enzyme levels. Clinical Pharmacology & Therapeutics (2003) 73, 435–455; doi: 10.1016/S0009‐9236(03)00014‐6

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0009-9236(03)00014-6

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 174

Metadata

Authors
Watanabe, I., Tomita, A., Shimizu, M., Sugawara, M., Yasumo, H., Koishi, R., Takahashi, T., Miyoshi, K., Nakamura, K., Izumi, T., Matsushita, Y., Furukawa, H., Haruyama, H., & Koga, T.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2003-05
Volume
73
Issue
5
Pages
435-455
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W2134992319
Cited by
174
References
5
FWCI
7.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1016/s0009-9236(03)00014-6
The paper
Watanabe, I., Tomita, A., Shimizu, M., Sugawara, M., Yasumo, H., Koishi, R., Takahashi, T., Miyoshi, K., Nakamura, K., Izumi, T., Matsushita, Y., Furukawa, H., Haruyama, H., & Koga, T. (2003). A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/s0009-9236(03)00014-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.